Paper41379320
Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
Alam U and 10 others. Naunyn Schmiedebergs Arch Pharmacol, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Papers, record 41379320. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41379320
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and safety of lorundrostat in uncontrolled hypertension: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypertension | Major topic |
| Antihypertensive Agents | Major topic |
| Blood Pressure | Major topic |
| Humans | |
| Randomized Controlled Trials as Topic | |
| Treatment Outcome | |
| Cytochrome P-450 CYP11B2 |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39656736 | Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases. | J Clin Endocrinol Metab | 2025 | https://conductscience.org/library/papers/39656736 | PubMed |
| 2 | 9310563 | Bias in meta-analysis detected by a simple, graphical test. | BMJ | 1997 | https://conductscience.org/library/papers/9310563 | PubMed |
| 3 | 21599961 | Use, tolerability and compliance of spironolactone in the treatment of heart failure. | BMC Clin Pharmacol | 2011 | https://conductscience.org/library/papers/21599961 | PubMed |
| 4 | 12423980 | Selected major risk factors and global and regional burden of disease. | Lancet | 2002 | https://conductscience.org/library/papers/12423980 | PubMed |
| 5 | 40587141 | Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. | JAMA | 2025 | https://conductscience.org/library/papers/40587141 | PubMed |
| 6 | 29133354 | 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | Hypertension | 2018 | https://conductscience.org/library/papers/29133354 | PubMed |
| 7 | 27502908 | Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. | Circulation | 2016 | https://conductscience.org/library/papers/27502908 | PubMed |
| 8 | 39270739 | Global burden of cardiovascular diseases: projections from 2025 to 2050. | Eur J Prev Cardiol | 2025 | https://conductscience.org/library/papers/39270739 | PubMed |
| 9 | 9308599 | Epidemiology and prevention of hypertension. | Med Clin North Am | 1997 | https://conductscience.org/library/papers/9308599 | PubMed |
| 10 | 34450083 | Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. | Lancet | 2021 | https://conductscience.org/library/papers/34450083 | PubMed |
| 11 | 39077590 | β-Blockers and Erectile Dysfunction in Heart Failure. Between Myth and Reality. | Rev Cardiovasc Med | 2022 | https://conductscience.org/library/papers/39077590 | PubMed |
| 12 | 12668699 | Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12668699 | PubMed |
| 13 | 40115559 | Prevalence and associated risk factors of hypertension in rural and urban areas of Punjab: A cross-sectional study. | J Family Med Prim Care | 2025 | https://conductscience.org/library/papers/40115559 | PubMed |
| 14 | 37690061 | Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37690061 | PubMed |
| 15 | 35390421 | Determining risk factors for triple whammy acute kidney injury. | Math Biosci | 2022 | https://conductscience.org/library/papers/35390421 | PubMed |
| 16 | 33782057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 17 | 31529687 | Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. | Arthritis Care Res (Hoboken) | 2020 | https://conductscience.org/library/papers/31529687 | PubMed |
| 18 | 26364544 | Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Lancet | 2015 | https://conductscience.org/library/papers/26364544 | PubMed |
| 19 | 37309038 | The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. | Nephrol Dial Transplant | 2023 | https://conductscience.org/library/papers/37309038 | PubMed |
| 20 | 26414968 | Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. | Lancet | 2015 | https://conductscience.org/library/papers/26414968 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42489850 | When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes. | Am J Cardiovasc Drugs | 2026 | https://conductscience.org/library/papers/42489850 | PubMed |
| 41714376 | The impact of acute normovolemic hemodilution on blood transfusions in cardiac surgery: a GRADE-assessed systematic review and meta-analysis of 30 randomized controlled trials with trial sequential analysis. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41714376 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP11B2 | 1585 | PubTator's text mining | https://conductscience.org/library/genes/1585 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41379320
GET https://conductscience.org/api/papers/v1/41379320/references?page=2